-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, major pharmaceutical companies have successively disclosed their 2021 annual reports.
About 70% of the companies reported good results
.
It can also be seen from these disclosed annual report data that a large number of pharmaceutical companies continue to increase their R&D investment
.
For example, Ascentage Pharma's annual report shows that in 2021, the company's R&D expenditure will be 767 million yuan, a year-on-year increase of 35.
8%
.
At present, Ascentage Pharma has built a rich and high-value global product pipeline, and most of the products under development have the potential of first-in-class or best-in-class
.
BeiGene's 2021 financial report shows that the company's R&D investment continues to expand, with a total investment of US$1.
459 billion in 2021, a year-on-year increase of 12.
7%
.
Among them, internal research and development expenses increased by 38.
3%, mainly because the company hired more research and development personnel, and compensation and welfare expenses increased by 109 million US dollars
.
Dizhe Pharmaceutical's financial report shows that during the reporting period, the company invested 588 million yuan in research and development, a year-on-year increase of 33.
70%
.
However, this also led to a further expansion of the company's losses, reaching 670 million yuan
.
The investor relations activity record sheet released by Watson Bio recently shows that the company's R&D investment in 2021 will be 754 million yuan, of which R&D expenses will be 621 million yuan, reaching a new high in recent years
.
With such a high investment in research and development, the company's research and development products have also made great progress
.
In recent years, Qilu Pharmaceutical has continued to accelerate the research and development of innovative drugs through research and development.
In 2021, the company's research and development investment will account for nearly 10% of sales revenue, reaching more than 3 billion yuan
.
It is reported that since 2022, the company's R&D investment has increased by 22.
9% year-on-year, and more than 80 innovative drug projects are under development
.
Baiyunshan vigorously promotes the sales growth of key varieties through scientific research and innovation
.
It is reported that the research and development expenses of Guangzhou Baiyun Mountain in 2021 will reach 875 million yuan, a year-on-year increase of 42.
94%, accounting for 1.
27% of the revenue.
.
Regarding the increase in R&D investment, Baiyunshan stated in the report that the main reason is that the company's subsidiaries have increased investment in special R&D expenses and R&D materials
.
Ascletis Pharmaceuticals will change from gross loss to gross profit in 2021.
During the reporting period, research and development expenses increased by 95.
5% from approximately RMB109.
1 million in 2020 to approximately RMB213.
3 million in 2021
.
Kunpharm has also made some efforts in research and development.
During the reporting period, Kunpharm’s R&D investment (including capital investment) totaled 136 million yuan, a year-on-year increase of 2.
98%, accounting for 3.
37% of industrial sales revenue; among which, R&D expense was 0.
87% 100 million yuan, accounting for 2.
16% of the industrial sales revenue
.
In addition, Baicheng Pharmaceutical mentioned in its recent announcement that R&D expenses increased by 142.
18% over the previous year.
The company has increased R&D investment.
On the other hand, the company continued to increase the research and development of innovative drugs
.
The continuous growth of R&D investment provides a strong guarantee for the improvement of the company's technological innovation capability and future performance
.
From the perspective of the general background, with the advancement of a series of domestic medical reform policies, the pharmaceutical industry has accelerated its transformation and upgrading, and traditional pharmaceutical companies have gradually transformed into innovative drugs and high-end generic drugs, posing challenges to the R&D capabilities of pharmaceutical companies
.
The industry pointed out that the level of R&D investment will affect the company's product R&D capability and progress to a certain extent.
From the perspective of domestic pharmaceutical companies that have successfully transformed themselves, the company's persistence in R&D and innovation is inseparable
.
In recent years, while some powerful local pharmaceutical companies have accelerated the progress of innovation and R&D in China, they have also actively carried out international cooperation and development, continuously deployed domestic and overseas markets, and improved their competitiveness and influence
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
About 70% of the companies reported good results
.
It can also be seen from these disclosed annual report data that a large number of pharmaceutical companies continue to increase their R&D investment
.
For example, Ascentage Pharma's annual report shows that in 2021, the company's R&D expenditure will be 767 million yuan, a year-on-year increase of 35.
8%
.
At present, Ascentage Pharma has built a rich and high-value global product pipeline, and most of the products under development have the potential of first-in-class or best-in-class
.
BeiGene's 2021 financial report shows that the company's R&D investment continues to expand, with a total investment of US$1.
459 billion in 2021, a year-on-year increase of 12.
7%
.
Among them, internal research and development expenses increased by 38.
3%, mainly because the company hired more research and development personnel, and compensation and welfare expenses increased by 109 million US dollars
.
Dizhe Pharmaceutical's financial report shows that during the reporting period, the company invested 588 million yuan in research and development, a year-on-year increase of 33.
70%
.
However, this also led to a further expansion of the company's losses, reaching 670 million yuan
.
The investor relations activity record sheet released by Watson Bio recently shows that the company's R&D investment in 2021 will be 754 million yuan, of which R&D expenses will be 621 million yuan, reaching a new high in recent years
.
With such a high investment in research and development, the company's research and development products have also made great progress
.
In recent years, Qilu Pharmaceutical has continued to accelerate the research and development of innovative drugs through research and development.
In 2021, the company's research and development investment will account for nearly 10% of sales revenue, reaching more than 3 billion yuan
.
It is reported that since 2022, the company's R&D investment has increased by 22.
9% year-on-year, and more than 80 innovative drug projects are under development
.
Baiyunshan vigorously promotes the sales growth of key varieties through scientific research and innovation
.
It is reported that the research and development expenses of Guangzhou Baiyun Mountain in 2021 will reach 875 million yuan, a year-on-year increase of 42.
94%, accounting for 1.
27% of the revenue.
.
Regarding the increase in R&D investment, Baiyunshan stated in the report that the main reason is that the company's subsidiaries have increased investment in special R&D expenses and R&D materials
.
Ascletis Pharmaceuticals will change from gross loss to gross profit in 2021.
During the reporting period, research and development expenses increased by 95.
5% from approximately RMB109.
1 million in 2020 to approximately RMB213.
3 million in 2021
.
Kunpharm has also made some efforts in research and development.
During the reporting period, Kunpharm’s R&D investment (including capital investment) totaled 136 million yuan, a year-on-year increase of 2.
98%, accounting for 3.
37% of industrial sales revenue; among which, R&D expense was 0.
87% 100 million yuan, accounting for 2.
16% of the industrial sales revenue
.
In addition, Baicheng Pharmaceutical mentioned in its recent announcement that R&D expenses increased by 142.
18% over the previous year.
The company has increased R&D investment.
On the other hand, the company continued to increase the research and development of innovative drugs
.
The continuous growth of R&D investment provides a strong guarantee for the improvement of the company's technological innovation capability and future performance
.
From the perspective of the general background, with the advancement of a series of domestic medical reform policies, the pharmaceutical industry has accelerated its transformation and upgrading, and traditional pharmaceutical companies have gradually transformed into innovative drugs and high-end generic drugs, posing challenges to the R&D capabilities of pharmaceutical companies
.
The industry pointed out that the level of R&D investment will affect the company's product R&D capability and progress to a certain extent.
From the perspective of domestic pharmaceutical companies that have successfully transformed themselves, the company's persistence in R&D and innovation is inseparable
.
In recent years, while some powerful local pharmaceutical companies have accelerated the progress of innovation and R&D in China, they have also actively carried out international cooperation and development, continuously deployed domestic and overseas markets, and improved their competitiveness and influence
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
